DeNovo Ventures was formed in 2000 by seasoned investors and experienced medical device entrepreneurs who sought to share the lessons
Business Model:
Revenue: $16.8M
Employees: 11-50
Address: 14612 Big Basin Way
City: Saratoga
State: CA
Zip: 95070
Country: US
DeNovo Ventures was formed in 2000 by seasoned investors and experienced medical device entrepreneurs who sought to share the lessons learned from a history of successful investing and building successful companies. They believed that their unique combination of skills and perspectives could help entrepreneurs to build companies which would have significant clinical impact and generate superior returns. Seven years later, this belief continues to hold true, demonstrated by investment success in selected medical device and biotechnology companies. With $650 million under management, De Novo has made more than 40 investments in medical devices and biotechnology across three funds. They invest in all stages of enterprise development and growth – from early stage to late stage. The unique background of leading companies as entrepreneurs and operating executives from start to exit enables us to advise entrepreneurs and management teams over the full life cycle of the company.
Contact Phone:
+16503291999
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2003 | iScience Interventional | Series C | 15M |
12/2009 | EBR Systems | Venture Round | 15M |
7/2007 | CardioMind | Series C | 11M |
3/2008 | CardioMind | Venture Round | 22M |
3/2004 | Spinal Kinetics | Series A | 10M |
10/2005 | EBR Systems | Series B | 21M |
10/2008 | InSound Medical | Series E | 13M |
2/2009 | SynergEyes | Series C | 0 |
3/2006 | Cartilix | Series B | 6.3M |
11/2007 | Viracta Therapeutics | Series A | 20M |
10/2007 | Vitreoretinal Technologies | Series A | 12M |
11/2005 | FlowMedica | Series D | 0 |
4/2010 | Viracta Therapeutics | Series B | 12M |
3/2004 | InSound Medical | Series D | 17.2M |
4/2010 | Articulinx Inc. | Series B | 10M |
3/2011 | Astute Medical | Series B | 13M |
8/2007 | Sierra Surgical | Series A | 7.1M |
7/2008 | Sierra Surgical | Series B | 14.5M |
5/2007 | Pulmonx | Series B | 20M |
11/2005 | Ovalis | Series A | 0 |
3/2012 | Viracta Therapeutics | Series B | 0 |
8/2001 | MicroVention Terumo | Series C | 12.5M |
3/2003 | iScience Surgical | Series B | 0 |
6/2004 | EBR Systems | Series A | 5.2M |
5/2010 | Astute Medical | Series B | 26.5M |
10/2005 | PhotoThera | Series B | 19M |
2/2011 | EBR Systems | Series D | 5M |
9/2013 | MyoScience | Series E | 0 |
3/2012 | MyoScience | Series D | 0 |
9/2011 | Simpirica Spine | Series C | 22M |
7/2008 | MyoScience | Series B | 0 |
8/2007 | EndoGastric Solutions | Series D | 30M |
6/2004 | Paracor Medical | Series C | 30.5M |
6/2007 | Paracor Medical | Series D | 44M |
6/2009 | Facet Solutions | Debt Financing | 4.1M |
5/2009 | PhotoThera | Series D | 50M |
6/2011 | Spinal Modulation | Series D | 0 |
7/2003 | Bacchus Vascular | Series D | 25M |
1/2016 | Benvenue Medical | Equity | 23M |
4/2006 | PhotoThera | Series C | 30.5M |
4/2017 | Avedro | Venture Round | 0 |
5/2014 | EndoGastric Solutions | Series G | 0 |
4/2006 | SynergEyes | Series B | 0 |
5/2007 | Talima Therapeutics | Series B | 19M |
5/2009 | iScience Interventional | Series F | 20.5M |
11/2008 | OncoMed Pharmaceuticals | Series B | 154M |
1/2002 | Renovis | Series B | 0 |
6/2008 | EBR Systems | Series C | 35M |
5/2007 | TRIA Beauty | Series D | 0 |
1/2006 | Spinal Kinetics | Series B | 36M |
3/2005 | iScience Surgical | Series C | 0 |
12/2005 | Facet Solutions | Series B | 16.5M |
2/2011 | Spiracur | Series C | 35M |
5/2005 | Bayhill Therapeutics | Series B | 35.4M |
1/2008 | Avedro | Series A | 8M |
4/2012 | WaveTec Vision | Venture Round | 0 |
2/2009 | WaveTec Vision | Series C | 20.1M |
1/2012 | iScience Interventional | Venture Round | 2.8M |
5/2010 | TearScience | Series C | 44.5M |
9/2009 | Spinal Kinetics | Debt Financing | 5.3M |
2/2011 | TRIA Beauty | Venture Round | 26.3M |
10/2012 | TRIA Beauty | Venture Round | 7.5M |
8/2010 | EndoGastric Solutions | Series F | 0 |
6/2009 | EndoGastric Solutions | Venture Round | 3.8M |
1/2008 | POINT Biomedical | Private Equity Round | 0 |
1/2003 | Lumend | Series D | 23.2M |
7/2013 | TRIA Beauty | Private Equity Round | 0 |
4/2016 | TearScience | Series D | 0 |
6/2012 | Astute Medical | Series C | 40.4M |
5/2011 | WaveTec Vision | Series D | 15.9M |
5/2007 | WaveTec Vision | Series B | 13M |
4/2011 | Benvenue Medical | Series C | 35.5M |
4/2006 | Bayhill Therapeutics | Venture Round | 15.8M |
1/2007 | TearScience | Series B | 15.1M |
6/2014 | Spinal Kinetics | Venture Round | 34M |
6/2009 | Spiracur | Series B | 20.3M |
1/2012 | Pulmonx | Private Equity Round | 0 |
1/2007 | Ovalis | Series B | 0 |
1/2006 | Spinal Modulation | Series A | 7M |
3/2010 | Pulmonx | Series C | 0 |
5/2018 | Avedro | Series F | 0 |
1/2023 | Milo | Series A | 0 |
4/2012 | EndoGastric Solutions | Venture Round | 0 |
5/2005 | Talima Therapeutics | Series A | 1.6M |
11/2009 | EndoGastric Solutions | Series E | 0 |
10/2009 | EndoGastric Solutions | Venture Round | 0 |
6/2012 | EndoGastric Solutions | Venture Round | 0 |
1/2008 | Benvenue Medical | Series B | 15M |
5/2008 | Astute Medical | Series A | 6.3M |
3/2013 | Avedro | Series D | 0 |
6/2012 | Benvenue Medical | Series D | 25M |
11/2009 | Spinal Modulation | Series C | 27.4M |
12/2007 | AxoGen | Post-IPO Equity | 12.1M |
7/2006 | InSound Medical | Series E | 18.9M |
2/2008 | InSound Medical | Series E | 11M |
6/2014 | Benvenue Medical | Series E | 40M |
5/2018 | Avedro | Series F | 0 |
4/2017 | Avedro | Venture Round | 0 |
4/2016 | TearScience | Series D | 0 |
1/2016 | Benvenue Medical | Series F | 0 |
6/2014 | Benvenue Medical | Series E | 0 |
6/2014 | Spinal Kinetics | Venture Round | 0 |
5/2014 | EndoGastric Solutions | Series G | 0 |
9/2013 | MyoScience | Series E | 0 |
7/2013 | TRIA Beauty | Private Equity Round | 0 |
3/2013 | Avedro | Series D | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|